

GamaSTAN

CareFirst Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info: 🗆 Same as Ro	questing Provider
Name:	NPI#:
Fax:	Phone:
Rendering Provider Info: ☐ Same as R	ferring Provider □ Same as Requesting Provider
Name:	NPI#:
Name: Fax:	NPI#: Phone: to dosing limits in accordance with FDA-approved labeling
Name:Fax:	Phone:
Name: Fax: Approvals may be subject accepted comp	Phone: to dosing limits in accordance with FDA-approved labeling endia, and/or evidence-based practice guidelines.
Name: Fax: Approvals may be subject accepted comp Required Demographic Information:	Phone:to dosing limits in accordance with FDA-approved labeling endia, and/or evidence-based practice guidelines.
Name: Fax: Approvals may be subject accepted comp Required Demographic Information: Patient Weight:	Phone: to dosing limits in accordance with FDA-approved labeling endia, and/or evidence-based practice guidelines. kgcm
Name: Fax: Approvals may be subject accepted comp Required Demographic Information: Patient Weight: Patient Height:	Phone: to dosing limits in accordance with FDA-approved labeling endia, and/or evidence-based practice guidelines. kgcm requested drug:

Criteria Questions:

1. What is the intended use for GamaSTAN?	
☐ Prophylaxis of hepatitis A, <i>Continue to 2</i>	
☐ Prophylaxis of measles (rubeola), <i>Continue to 5</i>	
☐ Prophylaxis of varicella (chickenpox), Continue to &	3
☐ Prophylaxis of rubella, <i>Continue to 11</i>	
☐ Other, please specify	_, No further questions
2. Was the patient exposed to hepatitis A virus within the childcare center or classroom contact with an infected particle of the patients of	he past 2 weeks (e.g., household contact, sexual contact, person)?
3. Is the patient exhibiting clinical manifestation of disc ☐ Yes, <i>No Further Questions</i> ☐ No, <i>No Further Questions</i>	ease?
4. Is the patient at high risk for exposure to hepatitis A are travelers to and workers in countries of high endem ☐ Yes, <i>No Further Questions</i> ☐ No, <i>No Further Questions</i>	virus (examples of populations at high risk for hepatitis A icity of infection and illicit drug users)?
5. Was the patient exposed to measles within the past 6 ☐ Yes, <i>Continue to 6</i> ☐ No, <i>Continue to 6</i>	days?
6. Has the patient ever received the measles vaccine (e. ☐ Yes, <i>Continue to 7</i> ☐ No, <i>Continue to 7</i>	g., MMR)?
7. Has the patient ever had the measles? ☐ Yes, No Further Questions ☐ No, No Further Questions	
8. Was the patient exposed to varicella within the past ☐ Yes, <i>Continue to 9</i> ☐ No, <i>Continue to 9</i>	10 days?
9. Is the patient at high risk for severe varicella (e.g., in ☐ Yes, <i>Continue to 10</i> ☐ No, <i>Continue to 10</i>	nmunocompromised, newborn/infant, pregnant woman)?
10. Is varicella zoster immune globulin (e.g., Varizig) r ☐ Yes, No Further Questions ☐ No, No Further Questions	not currently available?
11. Was the patient recently exposed to rubella? ☐ Yes, Continue to 12 ☐ No, Continue to 12	

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. GamaSTAN SGM 2067-A – 01/2025.

CVS Caremark Specialty Pharmacy

• 2211 Sanders Road NBT-6

• Northbrook, IL 60062

12. Is the patient currently pregnant?	
☐ Yes, No Further Questions	
☐ No, No Further Questions	
I attest that this information is accurate and true, and that doc information is available for review if requested by CVS Carem	11 0
,	11 0